Merck KGaA announces its largest investment in Asia
May 31, 2024
Source: drugdu
99
Merck KGaA Darmstadt Germany announced its largest investment in Asia through a ceremony of its € 300 million Bioprocessing Production Center in Daejeon, South Korea.
The new facility will accelerate the biotech and pharmaceutical industry’s development by manufacturing vaccines, cell and gene therapies, and protein-based therapies.
Once completed, the investment aims to create as many as 300 new jobs and continue to grow and support global demand for critical drugs and therapies.
The ceremony witnessed the presence of the leadership team of Merck including Matthias Heinzel- CEO of the Life Science business, Karen Madden- Chief Technology Officer, Life Science business, Sebastián Arana- Head, Process Solutions, Life Science business, Ivan Donzelot- Head of Integrated Supply Chain Operations. They were joined by Cheong Inkyo, Trade Minister of Korea, Lee Jang Woo, Mayor of Daejeon, Ambassador Georg Schmidt along with other dignitaries and partners.
Copyright©2024 Ddu. All rights reserved.
Read more on
- Taking advantage of the “Eight Measures of Science and Technology”, Haier Health aims to create a flagship of biotechnology December 24, 2024
- Beware of “two sets of prices” providing funding sources for pharmaceutical bribery December 24, 2024
- Is placebo effective? Vertex evaporates $13 billion overnight December 24, 2024
- Aadi Biosciences and WuXi Biologics collaborate to develop 3 new ADC drugs December 24, 2024
- Novo Nordisk’s talent war December 24, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
